Enhancement of cancer therapy efficacy by trastuzumab-conjugated and pH-sensitive nanocapsules with the simultaneous encapsulation of hydrophilic and hydrophobic compounds

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 10, Issue 1, 2014, Pages 99-107

  Chiang, Chih Sheng ^a   Hu, Shang Hsiu ^b   Liao, Bang Jie ^a   Chang, Yuan Ching ^c   Chen, San Yuan ^a  

^a NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

^b NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^c MACKAY MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Co delivery; Emulsion; HER 2 positive breast cancer; PH sensitive; Trastuzumab

Indexed keywords

BREAST CANCER; CO DELIVERIES; HYDROPHILIC AND HYDROPHOBIC; INTRAVENOUS INJECTIONS; MAGNETIC NANO-PARTICLES; PH SENSITIVE; POLY (VINYL ALCOHOL) (PVA); TRASTUZUMAB;

CHEMOTHERAPY; DISEASES; EMULSIFICATION; EMULSIONS; HYDROPHILICITY; HYDROPHOBICITY; NANOCAPSULES; ONCOLOGY;

MONOCLONAL ANTIBODIES;

DOUBLE EMULSION NANOCAPSULE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; NANOCAPSULE; PACLITAXEL; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; HYDROPHILICITY; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; MAGNETOTHERAPY; MOUSE; NANOENCAPSULATION; NONHUMAN; PH; PROTEIN EXPRESSION; THERAPY EFFECT;

CO-DELIVERY; EMULSION; HER-2 POSITIVE BREAST CANCER; PH SENSITIVE; TRASTUZUMAB;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CELL LINE, TUMOR; CELL SURVIVAL; DOXORUBICIN; DRUG DELIVERY SYSTEMS; EMULSIONS; FEMALE; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MICE; NANOCAPSULES; NEOPLASMS; PACLITAXEL; RECEPTOR, ERBB-2;

EID: 84891005610     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2013.07.009     Document Type: Article

References (33)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012, 62:10-29.
2. Blows F.M., Driver K.E., Schmidt M.K., et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 2010, 7:e1000279.
3. Lee J.H., Nan A. Combination drug delivery approaches in metastatic breast cancer. Journal of Drug Delivery 2012, 2012:17.
4. Wang Y., Gao S., Ye W.-H., Yoon H.S., Yang Y.-Y. Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer. Nat Mater. 2006, 5:791-796.
5. Lindley C., McCune J.S., Thomason T.E., et al. Perception of chemotherapy side effects cancer versus noncancer patients. Cancer Pract. 1999, 7:59-65.
6. Carelle N., Piotto E., Bellanger A., Germanaud J., Thuillier A., Khayat D. Changing patient perceptions of the side effects of cancer chemotherapy. Cancer. 2002, 95:155-163.
7. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986, 46:6387-6392.
8. Torchilin V.P. Micellar nanocarriers: pharmaceutical perspectives. Pharm Res. 2007, 24:1-16.
9. Maeda H., Bharate G.Y., Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm. 2009, 71:409-419.
10. Torchilin V.P. Multifunctional nanocarriers. Adv Drug Del Rev. 2006, 58:1532-1555.
11. Danhier F., Feron O., Préat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Controlled Release. 2010, 148:135-146.
12. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New Engl J Med. 2001, 344:783-792.
13. Nahta R., Hung M.-C., Esteva F.J. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res. 2004, 64:2343-2346.
14. Morris M.J., Reuter V.E., Kelly W.K., et al. HER-2 profiling and targeting in prostate carcinoma. Cancer 2002, 94:980-986.
15. Lee A.L.Z., Wang Y., Cheng H.Y., Pervaiz S., Yang Y.Y. The co-delivery of paclitaxel and Herceptin using cationic micellar nanoparticles. Biomaterials 2009, 30:919-927.
16. Wang Y., Chen J., Irudayaraj J. Nuclear targeting dynamics of gold nanoclusters for enhanced therapy of HER2+ breast cancer. ACS Nano. 2011, 5:9718-9725.
17. Yang T., Choi M.-K., Cui F.-D., et al. Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome. J Controlled Release. 2007, 120:169-177.
18. Chiu G.N.C., Edwards L.A., Kapanen A.I., et al. Modulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructs. Mol Cancer Ther. 2007, 6:844-855.
19. Adams G.P., Weiner L.M. Monoclonal antibody therapy of cancer. Nat Biotech. 2005, 23:1147-1157.
20. Yang H.-W., Hua M.-Y., Liu H.-L., et al. Cooperative dual-activity targeted nanomedicine for specific and effective prostate cancer therapy. ACS Nano. 2012, 6:1795-1805.
21. Chertok B., Moffat B.A., David A.E., et al. Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. Biomaterials 2008, 29:487-496.
22. Hu S.-H., Liao B.-J., Chiang C.-S., Chen P.-J., Chen I.W., Chen S.-Y. Core-shell nanocapsules stabilized by single-component polymer and nanoparticles for magneto-chemotherapy/hyperthermia with multiple drugs. Adv Mater. 2012, 24:3627-3632.
23. Kumar S., Dory Y.L., Lepage M., Zhao Y. Surface-grafted stimuli-responsive block copolymer brushes for the thermo-, photo- and pH-sensitive release of dye molecules. Macromolecules 2011, 44:7385-7393.
24. Zelikin A.N., Quinn J.F., Caruso F. Disulfide cross-linked polymer capsules: en route to biodeconstructible systems. Biomacromolecules. 2005, 7:27-30.
25. Schüwer N., Klok H.-A. Tuning the pH sensitivity of poly(methacrylic acid) brushes. Langmuir. 2011, 27:4789-4796.
26. Yessine M.-A., Leroux J.-C. Membrane-destabilizing polyanions: interaction with lipid bilayers and endosomal escape of biomacromolecules. Adv Drug Del Rev. 2004, 56:999-1021.
27. Lee A.L.Z., Wang Y., Pervaiz S., Fan W., Yang Y.Y. Synergistic anticancer effects achieved by Co-delivery of TRAIL and paclitaxel using cationic polymeric micelles. Macromol Biosci. 2011, 11:296-307.
28. Xiong X.-B., Lavasanifar A. Traceable multifunctional micellar nanocarriers for cancer-targeted co-delivery of MDR-1 siRNA and doxorubicin. ACS Nano. 2011, 5:5202-5213.
29. Wang H., Zhao Y., Wu Y., et al. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. Biomaterials. 2011, 32:8281-8290.
30. Hu C.-M.J., Zhang L. Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem Pharmacol. 2012, 83:1104-1111.
31. Parhi P., Mohanty C., Sahoo S.K. Nanotechnology-based combinational drug delivery: an emerging approach for cancer therapy. Drug Discov Today. 2012, 17:1044-1052.
32. Pegram M., Hsu S., Lewis G., et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene. 1999, 18:2241-2251.
33. Du J.Z., O'Reilly R.K. Advances and challenges in smart and functional polymer vesicles. Soft Matter. 2009, 5:3544-3561.